ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS grows its fibrosis portfolio

by Lisa M. Jarvis
November 14, 2016 | APPEARED IN VOLUME 94, ISSUE 45

Bolstering its growing portfolio of fibrosis treatments, Bristol-Myers Squibb has paid $100 million upfront for access to Nitto Denko’s siRNA molecules targeting heat shock protein 47. Nitto Denko’s lead HSP47 inhibitor, which blocks a protein responsible for regulating collagen synthesis and deposition, is in Phase Ib studies to treat advanced liver fibrosis caused by nonalcoholic steatohepatitis. BMS has in recent years assembled a pipeline of fibrosis assets through deals that include options to buy Galecto Biotech and Promedior.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment